Highlights
– In a small cohort of patients with metastatic melanoma (n=14 evaluable), low‑dose subcutaneous IL‑2 after lymphodepletion and TIL infusion produced clinical outcomes comparable to high‑dose intravenous IL‑2 when followed by pembrolizumab.
– Overall response rates were low in both arms; one durable ongoing partial response (>76 months) occurred in the low‑dose arm.
